The Foundation, in collaboration with external community advisors, finalizes recommendations in area of Community to help foster more inclusion and improve the experiences of Black people living with and impacted by cystic fibrosis.
Breadth of expertise in business, philanthropy, community engagement, and venture capital to help advance Foundation’s mission
Aug. 9, 2023
|
4 min read
The U.S. Food and Drug Administration approved Kalydeco® (ivacaftor) for infants as young as 1 month who have at least one copy of 97 mutations that have proven to be responsive to Kalydeco.
May 3, 2023
|
4 min read
Groups urging need for revitalizing antimicrobial development call for passage of the bill this year
April 27, 2023
|
3 min read
With this approval, approximately 2,250 children in the U.S. will be eligible for Trikafta® (elexacaftor/tezacaftor/ivacaftor), including more than 900 who will have access to a CFTR modulator for the first time. The Cystic Fibrosis Foundation believes it is beneficial to start people with cystic fibrosis on modulators as early as possible to help prevent lung damage and the onset of complications.
April 26, 2023
|
3 min read
Human resources veteran Massenburg brings more than 20 years of leadership experience in nonprofit and business sectors
April 5, 2023
|
3 min read
Brown to join Foundation in April 2023, bringing more than 20 years of experience in nonprofit communications and journalism, with a focus on health and science
March 29, 2023
|
4 min read
The Foundation seeks to advance its mission by making improvements in key areas of health equity and outcomes and diverse workforce development.
Feb. 15, 2023
|
3 min read
The Foundation’s commitment to these principles will continue to be a cornerstone of the Foundation’s work to advance our mission in 2023.
Jan. 19, 2023
|
4 min read